| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:51:58 UTC |
|---|
| HMDB ID | HMDB0015372 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Clomipramine |
|---|
| Description | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette's disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. |
|---|
| Structure | CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2 InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethyl-1-propanamine | ChEBI | | 3-(3-CHLORO-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine | ChEBI | | 3-Chloroimipramine | ChEBI | | Chlorimipramine | ChEBI | | g 34586 | ChEBI | | Monochlorimipramine | ChEBI | | Anafranil | Kegg | | Monohydrochloride, clomipramine | HMDB | | Clomipramine maleate (1:1) | HMDB | | Clomipramine monohydrochloride | HMDB | | Hydiphen | HMDB | | Hydrochloride, clomipramine | HMDB | | Chlomipramine | HMDB | | Clomipramine hydrochloride | HMDB |
|
|---|
| Chemical Formula | C19H23ClN2 |
|---|
| Average Molecular Weight | 314.852 |
|---|
| Monoisotopic Molecular Weight | 314.154976453 |
|---|
| IUPAC Name | (3-{14-chloro-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}propyl)dimethylamine |
|---|
| Traditional Name | clomipramine |
|---|
| CAS Registry Number | 303-49-1 |
|---|
| SMILES | CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2 |
|---|
| InChI Identifier | InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 |
|---|
| InChI Key | GDLIGKIOYRNHDA-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dibenzazepines. Dibenzazepines are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzazepines |
|---|
| Sub Class | Dibenzazepines |
|---|
| Direct Parent | Dibenzazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dibenzazepine
- Alkyldiarylamine
- Tertiary aliphatic/aromatic amine
- Azepine
- Benzenoid
- Aryl halide
- Aryl chloride
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organopnictogen compound
- Amine
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 189.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.014 g/L | Not Available | | LogP | 4.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 174.3 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.31 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.2555 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.29 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 37.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1350.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 268.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 176.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 184.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 122.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 419.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 427.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 498.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1194.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 429.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1336.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 283.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 362.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 316.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 217.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Clomipramine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-9060000000-34352b7b1b6a78a55cd8 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Clomipramine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-066r-6391000000-e57dc447a97807ce527a | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QTOF , positive-QTOF | splash10-052r-9010000000-77a0afe2d49df71431d8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-014i-2009000000-a1cc70dad4bb4c19ab7b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-000i-9000000000-a9af3369f8d6da434fd0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-052r-9000000000-3f1941447bc096ea9d73 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4r-9010000000-c6b5c5a56ac456cd8845 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4i-9010000000-8b5307526ea875a06881 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4i-9010000000-98746d4db184914ce871 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4i-9310000000-194486cca11709cd1b80 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4i-9600000000-da861dd5252aaff30e89 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine LC-ESI-QFT , positive-QTOF | splash10-0a4i-6900000000-efdead8e50e8b700d4bd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine Linear Ion Trap , positive-QTOF | splash10-00di-0090000000-558a68c9d4919e7945a2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine Linear Ion Trap , positive-QTOF | splash10-00di-0090000000-489c71d87d96f5bafd40 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine Linear Ion Trap , positive-QTOF | splash10-014i-0009002000-3318f523b446a8d9d68e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine Linear Ion Trap , positive-QTOF | splash10-014i-0009000000-8b8a1763c5358415b2b0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine 60V, Positive-QTOF | splash10-0a4r-9000000000-5c2c7aa10719beb2c160 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine 45V, Positive-QTOF | splash10-052r-9000000000-252b037815db33ff1554 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine 15V, Positive-QTOF | splash10-014i-4009000000-f6fbb8f3c1432560c648 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine 30V, Positive-QTOF | splash10-000i-9000000000-96e4294b38c6773a9dff | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clomipramine 10V, Positive-QTOF | splash10-014r-8009000000-47296607dea9797c1439 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 10V, Positive-QTOF | splash10-014i-1029000000-68c9c186daeb14b564b2 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 20V, Positive-QTOF | splash10-01bl-7095000000-7aeedc02e87a2acd87ab | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 40V, Positive-QTOF | splash10-0076-9140000000-201084960b40747f3339 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 10V, Negative-QTOF | splash10-03di-0009000000-0d5e3470f9eae466d2e1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 20V, Negative-QTOF | splash10-03fr-1089000000-bda0b94a0a3d33589f39 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clomipramine 40V, Negative-QTOF | splash10-0fbc-2390000000-f1f3b5dec72ac0b8b633 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|